L'apathie Dans La Schizophrénie: Étude Neuropsychologique Et Anatomique
Data Collection
Collected at a single point in time - Cross-sectionalMental Disorders+6
+ Nervous System Diseases
+ Neurologic Manifestations
Case-Control
Comparing exposures between individuals with and without disease in order to identify potential risk factors.Summary
Study start date: June 1, 2012
Actual date on which the first participant was enrolled.Apathy, defined as a quantitative reduction of voluntary, goal-directed behaviours (GDB), is a core component of negative symptoms. It has been suggested that the physiopathology of apathy is not a single entity but may be multiple, depending on which specific process or macrofunction is disrupted during completion of GDB. In line with this notion, Levy and Dubois proposed dividing apathic syndromes into three subtypes of disrupted processing: 'a-motivation', 'cognitive inertia', and 'uncoupling'. In schizophrenia, apathy has been associated with executive dysfunction, functional impairment and poor outcome. However, the neurobiological underpinnings of apathy in schizophrenia are poorly understood. Primary objective: confirm that chronic schizophrenic patients are apathic compared to healthy volunteers Secondary objectives: investigate if apathy is related to a particular aspect of the disease (i.e. negative, positive symptomatology and/or deficit form) investigate if apathy correlates with executive dysfunction investigate if apathy is associated with a specific mechanism using an experimental task specially designed to investigate the different mechanism (i.e. 'a-motivation', 'cognitive inertia', and 'uncoupling') investigate if there is a volumetric abnormality affecting the executive system in apathic schizophrenic patients link these eventual volumetric abnormalities to prefrontal cortex-basal ganglia circuits according to a specific subtype of apathy in the apathic schizophrenic group
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.60 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Case-Control
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 20 to 55 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria (healthy volunteers): Male or Female aged 20 to 55 years old included Under French public assurance system Exclusion Criteria (healthy volunteers): Personal history of neurological disorders Personal history of head injury Alcohol or substance abuse Under psychotropic drug Contraindication for MRI Inclusion Criteria (schizophrenic patients): Male or Female aged 20 to 55 years old included Under French public assurance system diagnosis of schizophrenia according to the DSM-IV R criteria Duration of illness > 5 years clinical stability during the past 2 months (defined as no treatment modification or hospitalisation 2 months prior evaluation) Exclusion Criteria (schizophrenic patients): Schizo-affective disorder Personal history of neurological disorders Personal history of head injury Alcohol or substance abuse Contraindication for MRI
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière
Paris, FranceOpen INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière in Google Maps